| Literature DB >> 33935934 |
Nina M Mansoor1, Tishok Vanniyasingam1, Ian Malone2, Nicola Z Hobbs1, Elin Rees3, Alexandra Durr4, Raymund A C Roos5, Bernhard Landwehrmeyer6, Sarah J Tabrizi1, Eileanoir B Johnson1, Rachael I Scahill1.
Abstract
Background: Neuroimaging shows considerable promise in generating sensitive and objective outcome measures for therapeutic trials across a range of neurodegenerative conditions. For volumetric measures the current gold standard is manual delineation, which is unfeasible for samples sizes required for large clinical trials.Entities:
Keywords: FIRST; FreeSurfer; Huntington (disease); MALP-EM; STEPS; automated segmentation; caudate
Year: 2021 PMID: 33935934 PMCID: PMC8079754 DOI: 10.3389/fneur.2021.616272
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Participant demographics.
| Number | 35 | 46 |
| Age mean ± SD (range) | 51.03 ± 8.8 (28–66) | 49 ± 9.6 (26–67) |
| Gender: M/F | 15/20 (−1) | 16 (−2)/30 |
| Site: Leiden/London/Paris/Ulm | 9/10/8 (−1)/8 | 12/14/8/12 (−2) |
| CAG repeat mean ± SD, (range) | NA | 43.3 ± 2.79 (39–54) |
| Disease burden mean ± SD (range) | NA | 371.59 ± 89.04 (226–559) |
CAG, cytosine-adenine-guanine; HD, Huntington’s disease; NA, Not applicable.
One female control subject from Paris and 2 male HD subjects from Ulm were excluded after quality control of segmentations (gross failure was identified, and segmentations deemed biologically implausible). These were not included in the quantitative volumetric analysis. Final sample was therefore n = 78.
Raw caudate volume and effect sizes (Cohen’s d) for all techniques (manual and automated tools).
| Manual | 7674 ± 842 (6123–10080) | 5168 ± 1025 (3436–8643) | 2506 (2074–2938) | <0.001 | 2.639 (2.021–3.247) |
| FIRST | 6779 ± 782 (5205–8451) | 4715 ± 794 (3197–7130) | 2064 (1706–2423) | <0.001 | 2.616 (2.001–3.222) |
| FreeSurfer | 7618 ± 933 (6131–9549) | 5137 ± 1024 (3314–8464) | 2481 (2033–2929) | <0.001 | 2.517 (1.913–3.112) |
| STEPS | 7306 ± 821 (5975–8689) | 4826 ± 1007 (3189–7946) | 2480 (2057–2904) | <0.001 | 2.664 (2.044–3.275) |
| MALP-EM | 6666 ± 1075 (4406–8664) | 4374 ± 1111 (2232–6530) | 2291 (1793–2790) | <0.001 | 2.091 (1.530–2.644) |
Mean diff, mean difference; CI, confidence Interval; SD, standard deviation; dof, degrees of freedom.
Figure 1Boxplots showing caudate volumes separated by group for each segmentation tool including manual segmentation. Boxes show first quartile, median and third quartile with whiskers representing the smallest and largest volumes. Dots represent outliers. Independent t-tests for each method demonstrated significant volume differences at 95% CI between the two groups, all p < 0.0001.
Figure 2Boxplot demonstrating caudate volume outputs by disease state (HD=1, Controls=0) and site. Boxes show first quartile, median and third quartile with whiskers represent the smallest and largest volumes. Dots represent outliers. More outliers were found at the Ulm site.
Figure 3Boxplot demonstrating Jaccard Indices (as a ratio) for each automated method ROI with manual ROI. Boxes show first quartile, median and third quartile with whiskers represent the smallest and largest volumes. Dots represent outliers. STEPS segmented ROIs had larger overlaps with manually segmented ROI in both controls and HD subjects (closest to 1).
Group comparisons of cBSI and normalized cBSI outputs by baseline caudate segmentation method.
| Manual | 76.819 | 193.140 | −116.320 | −0.949 | 0.009 | 0.040 | −0.031 | −1.340 |
| FIRST | 79.840 | 194.695 | −114.855 | −0.961 | 0.011 | 0.043 | −0.032 | −1.343 |
| FreeSurfer | 73.518 | 172.295 | −98.776 | −0.720 | 0.009 | 0.035 | −0.026 | −1.049 |
| STEPS | 78.442 | 201.298 | −122.856 | −1.048 | 0.010 | 0.045 | −0.034 | −1.396 |
| MALP-EM | 64.936 | 208.824 | −143.888 | −1.154 | 0.010 | 0.052 | −0.043 | −1.522 |
cBSI, caudate Boundary Shift Integral (a measure of longitudinal caudate atrophy); Mean diff, mean difference; CI, confidence Interval; SD, standard deviation.